Breakthrough brain tumour blood test

A new study has just been published with a significant breakthrough in a research programme proudly funded by Action Against Cancer.

The team at the University of Sussex, in collaboration with scientists from different institutes worldwide, have identified a blood test capable of early diagnosis of the most aggressive form of brain tumour, called glioblastoma. Earlier diagnosis saves lives.

Led by Professor Georgios Giamas the researchers have identified molecules within patient blood samples which could signal the presence of glioblastoma. This is the most common high grade primary brain tumour in adults, and diagnosis currently often requires risky brain surgery.

Professor Giamas said: "Currently, glioblastoma detection relies on the display of symptoms, magnetic resonance imaging and invasive tissue biopsies - all of which can delay the identification of the tumour. Early diagnosis for any type of cancer is crucial, but it is particularly so for glioblastoma, which is often diagnosed late."

The research team have created a highly accurate test by analysing the cargo of tiny particles that are released by cells into the bloodstream. The specific biomarkers they have discovered reliably identify glioblastoma.

Results from the research suggest the test could also monitor how a patient is responding to therapy. In addition, the method used showed promising results in differentiating between types of brain tumours, which is crucial for choosing the right treatment.

Professor Giamas said: "This is fantastic news because we've shown that via a simple, cost-effective blood test we can identify a robust biomarker signature that can detect even the most aggressive brain tumours with remarkable accuracy.

This discovery could save lives by replacing risky brain surgery with a rapid, minimally invasive test that delivers answers in days rather than weeks, allowing treatment to begin at the earliest possible moment.

The next critical step is creating consistent procedures across hospitals and launching larger studies to bring this blood test from the laboratory into routine clinical practice, where it can truly transform patient outcomes."

The groundbreaking study linked herehas been published in the highly respected journal Cell Reports Medicine.